Thursday, July 23, 2026

pharma · Breast Cancer · Multiple Sclerosis (MS)

HOFFMANN-LA ROCHE

Hoffmann-La Roche is a pharma organization headquartered in Basel, CH. Primary therapeutic focus areas include Breast Cancer, Multiple Sclerosis (MS), Spinal Muscular Atrophy (SMA), Non-Small Cell Lung Cancer, Solid Tumo

Mississauga, Ontario L5N 5M8, CA HQ
10 Employees
NMPA registrant Type
Company details
Status
Public
HQ
Mississauga, Ontario L5N 5M8, CA
Employees
10
Programs
4
Drugs
155
Patents
0
Clinical program

lebrikizumab

Phase 3 · small molecule · Asthma

lebrikizumab for Asthma is a Phase 3 program (small_molecule) at Hoffmann-La Roche with 2 ClinicalTrials.gov record(s).

← All Hoffmann-La Roche projects Phase 3 small molecule completed

Internal code WA29249

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
Hoffmann-La Roche
Phase
Phase 3
Modality
small_molecule
Indication
Asthma
Status
completed
Trials
2